Volume 22 Issue 6
Jun.  2024
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2024  >  22(6): 966-970
ZHAI Xinying, WANG Lihua, LI Yanhua. Expression of PD-1 and PD-L1 in platinum-resistant ovarian epithelial carcinoma and their clinical significance[J]. Chinese Journal of General Practice, 2024, 22(6): 966-970. doi: 10.16766/j.cnki.issn.1674-4152.003545
Citation: ZHAI Xinying, WANG Lihua, LI Yanhua. Expression of PD-1 and PD-L1 in platinum-resistant ovarian epithelial carcinoma and their clinical significance[J]. Chinese Journal of General Practice, 2024, 22(6): 966-970. doi: 10.16766/j.cnki.issn.1674-4152.003545
shu

Expression of PD-1 and PD-L1 in platinum-resistant ovarian epithelial carcinoma and their clinical significance

doi: 10.16766/j.cnki.issn.1674-4152.003545

  • Department of Gynaecologic Oncology, the First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui 233004, China

Funds:

 KJ2021A0720

  • Received Date: 2023-08-14
    Available Online: 2024-07-22
    Abstract
  •   Objective  To investigate the expression of programmed death receptor 1 (PD-1) and programmed death receptor-ligand 1 (PD-L1) in the tissues of patients with platinum-resistant ovarian epithelial cancer, and to analyze the relationship between the expression of PD-1 and PD-L1 in patients with platinum-resistant ovarian epithelial cancer and clinical characteristics and prognosis.  Methods  The tissue paraffin blocks of 111 patients with ovarian cancer (71 cases of platinum-resistant tissue paraffin blocks and 40 cases of platinum-sensitive tissue paraffin blocks) who underwent surgical treatment in the First Affiliated Hospital of Bengbu Medical University from January 2018 to June 2021 were collected, and 10 cases of benign ovarian tissue paraffin blocks were taken as controls. The expression levels of PD-1 and PD-L1 in ovarian cancer tissues were detected by ELiVisionTM immunohistochemistry method, and the relationships between the expression levels and pathological features and prognosis were analyzed.  Results  The positive rates of PD-1 and PD-L1 in the platinum-sensitive group and platinum-resistant group were 22.5%, 32.5% and 42.3%, 53.5%, respectively. The positive rates of PD-1 and PD-L1 in the drug-resistant group were higher than those in the platinum-sensitive group (P < 0.05). The positive expression rates of PD-1 and PD-L1 in serous and non-serous cancer tissues were 50.0%, 61.5% and 21.1%, 31.6%, respectively. The positive expression rates of PD-1 and PD-L1 in surgical pathological stage Ⅲ-Ⅳ and Ⅰ-Ⅱ were 51.0%, 63.3 %, and 22.7%, 31.8%, respectively. The expressions of PD-1 and PD-L1 were significantly lower than those in serous carcinoma and stage Ⅲ to Ⅳ patients, with statistical significance (P < 0.05). The multifactorial Cox proportional risk model shows: PD-1 positive group (HR=3.905, P=0.001), PD-L1 positive group (HR=4.581, P=0.002), surgical pathological stage Ⅲ and Ⅳ stages (HR=3.948, P=0.026) were independent risk prognostic factors affecting survival of patients with platinum-resistant ovarian epithelial cancer. Survival analysis showed that the two-year survival rate of PD-1 and PD-L1 positive patients were lower than that of negative patients (P < 0.05).  Conclusion  The high expression of PD-1 and PD-L1 in ovarian epithelial carcinoma tissues is related to drug resistance, which leads to malignant progression of tumor and shortened survival time, and is one of the indicators of poor prognosis of patients.

     

    • FullText(HTML)
  • loading
    • References(21)
  • [1]
    SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. doi: 10.3322/caac.21660
    [2]
    HAVASI A, CAINAP S S, HAVASI A T, et al. Ovarian cancer-insights into platinum resistance and overcoming it[J]. Medicina Kaunas, 2023, 59(3): 544. DOI: 10.3390/medicina59030544.
    [3]
    TORRE L A, TRABERT B, DESANTIS C E, et al. Ovarian cancer statistics, 2018[J]. CA Cancer J Clin, 2018, 68(4): 284-296. doi: 10.3322/caac.21456
    [4]
    WALLIS B, BOWMAN K R, LU P, et al. The challenges and prospects of P53-based therapies in ovarian cancer[J]. Biomolecules, 2023, 13(1): 159. DOI: 10.3390/biom13010159.
    [5]
    PAWLOWSKA A, SKIBA W, SUSZCZYK D, et al. The dual blockade of the TIGIT and PD-1/PD-L1 pathway as a new hope for ovarian cancer patients[J]. Cancers(Basel), 2022, 14(23): 5757. DOI: 10.3390/cancers14235757.
    [6]
    WANG Y M, CAI W, XUE Q M, et al. Prognostic role of different PD-L1 expression patterns and tumor-infiltrating lymphocytes in high-grade serous ovarian cancer: a systematic review and meta-analysis[J]. Front Immunol, 2023, 14: 1234894. DOI: 10.3389/fimmu.2023.1234894.
    [7]
    闫风彩, 金木兰, 石峰, 等. PD-1/PD-L1在恶性肿瘤中的表达及研究进展[J]. 诊断病理学杂志, 2019, 26(1): 61-65. doi: 10.3969/j.issn.1007-8096.2019.01.018

    YAN F C, JIN M L, SHI F, et al. Expression and research progress of PD-1/PD-L1 in malignant tumors[J]. Chinese Journal of Diagnostic Pathology, 2019, 26(1): 61-65. doi: 10.3969/j.issn.1007-8096.2019.01.018
    [8]
    WANG D R, WU X L, SUN Y L. Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response[J]. Signal Transduct Target Ther, 2022, 7(1): 331. DOI: 10.1038/s41392-022-01136-2.
    [9]
    高五岳, 郭园园, 刘贝贝, 等. 不同距离癌旁组织PD-1和PD-L1表达对肾部分切除术边距选择的临床意义[J]. 中华全科医学, 2019, 17(12): 2004-2007, 2034. doi: 10.16766/j.cnki.issn.1674-4152.001113

    GAO W Y, GUO Y Y, LIU B B, et al. The clinical significance of PD-1 and PD-L1 expression in different distance paracancer tissues in selection of margin for partial nephrectomy[J]. Chinese Journal of General Practice, 2019, 17(12): 2004-2007, 2034. doi: 10.16766/j.cnki.issn.1674-4152.001113
    [10]
    鞠策, 高景春, 张朋新, 等. PD-1和PD-L1在卵巢上皮性癌组织中的表达及其意义[J]. 中华妇产科杂志, 2020, 55(8): 529-534. doi: 10.3760/cma.j.cn112141-20200301-00155

    JU C, GAO J C, ZHANG P X, et al. Expression and significance of PD-1 and PD-L1 in ovarian epithelial carcinoma[J]. Chinese Journal of Obstetrics and Gynecology, 2020, 55(8): 529-534. doi: 10.3760/cma.j.cn112141-20200301-00155
    [11]
    彩琴. 上皮性卵巢癌患者的临床病理情况分析[J]. 实用妇科内分泌电子杂志, 2022, 9(11): 14-17. https://www.cnki.com.cn/Article/CJFDTOTAL-FKDZ202211004.htm

    CAI Q. Clinicopathological analysis of patients with epithelial ovarian cancer[J]. Electronic Journal of Gynecologic Endocrinology, 2022, 9(11): 14-17. https://www.cnki.com.cn/Article/CJFDTOTAL-FKDZ202211004.htm
    [12]
    赵玲军. 卵巢癌靶向治疗新进展[J]. 现代实用医学, 2019, 31(7): 854-857. doi: 10.3969/j.issn.1671-0800.2019.07.003

    ZHAO L J. New progress of targeted therapy for ovarian cancer[J]. Modern Practical Medicine, 2019, 31(7): 854-857. doi: 10.3969/j.issn.1671-0800.2019.07.003
    [13]
    王丝雨, 王娜, 张兰, 等. PD-1和PD-L1在卵巢上皮性癌组织中的表达及其与免疫抑制相关因子的关联[J]. 实用癌症杂志, 2022, 37(7): 1076-1079. doi: 10.3969/j.issn.1001-5930.2022.07.007

    WANG S Y, WANG N, ZHANG L, et al. Expression of PD-1 and PD-L1 in ovarian epithelial carcinoma and their association with immunosuppressive factors[J]. Journal of Practical Cancer, 2022, 37(7): 1076-1079. doi: 10.3969/j.issn.1001-5930.2022.07.007
    [14]
    陈洪丞成, 张宏权, 魏潇凡. PD-L1表达及其调控在肿瘤治疗中作用的研究进展[J]. 生理科学进展, 2023, 54(6): 526-532. https://www.cnki.com.cn/Article/CJFDTOTAL-SLKZ202306010.htm

    CHEN H C C, ZHANG H Q, WEI X F. Research progress of PD-L1 expression and its regulation in the treatment of tumor[J]. Advances in Physiological Sciences, 2023, 54(6): 526-532. https://www.cnki.com.cn/Article/CJFDTOTAL-SLKZ202306010.htm
    [15]
    毛若南, 姜伟. PD-1/PD-L1免疫抑制剂治疗卵巢癌的临床应用进展[J]. 国际妇产科学杂志, 2021, 48(6): 605-609. https://www.cnki.com.cn/Article/CJFDTOTAL-GWVC202106002.htm

    MAO R N, LIANG W. Clinical application progress of PD-1/PD-L1 immunosuppressive agents in the treatment of ovarian cancer[J]. International Journal of Obstetrics and Gynecology, 2021, 48(6): 605-609. https://www.cnki.com.cn/Article/CJFDTOTAL-GWVC202106002.htm
    [16]
    张智, 张一琼. Foxp3+Tregs及PD1在上皮性卵巢癌组织中的表达及其临床病理意义[J]. 南昌大学学报(医学版), 2018, 58(5): 54-58, 69. https://www.cnki.com.cn/Article/CJFDTOTAL-JXYB201805012.htm

    ZHANG Z, ZHANG Y Q. The expression and clinical pathological significance of Foxp3+Tregs and PD1 in epithelial ovarian cancer tissue[J]. Journal of Nanchang University (Medical Edition), 2018, 58(5): 54-58, 69. https://www.cnki.com.cn/Article/CJFDTOTAL-JXYB201805012.htm
    [17]
    袁风玲, 贾淑慧, 江源. 卵巢癌组织中PD-L1及PD-L2的表达及其预后判断价值[J]. 实用癌症杂志, 2020, 35(10): 1622-1624, 1638. doi: 10.3969/j.issn.1001-5930.2020.10.015

    YUAN F L, JIA S H, JIANG Y. Expression and prognostic value of PD-L1 and PD-L2 in ovarian cancer tissue[J]. Journal of Practical Cancer, 2020, 35(10): 1622-1624, 1638. doi: 10.3969/j.issn.1001-5930.2020.10.015
    [18]
    WANG Y F, ZHU X H, Li C. Analysis of the relationship between LncRNA and PD-L1 expression and chemotherapy resistance in ovarian cancer patients[J]. 中国医学创新, 2022, 19(11): 169-173. doi: 10.3969/j.issn.1674-4985.2022.11.042
    [19]
    杨蓉, 张春莉. PD-1和PD-L1在卵巢癌中的研究进展[J]. 延安大学学报(医学科学版), 2019, 17(1): 94-96, 101. https://www.cnki.com.cn/Article/CJFDTOTAL-YAXY201901026.htm

    YANG R, ZHANG C L. Research progress of PD-1 and PD-L1 in ovarian cancer[J]. Journal of Yan'an University (Medical Science Edition), 2019, 17(1): 94-96, 101. https://www.cnki.com.cn/Article/CJFDTOTAL-YAXY201901026.htm
    [20]
    杜晓丽, 张东明, 徐洪. 卵巢癌组织中PD-1、PD-L1和Cyclin D1蛋白表达与预后的关系[J]. 分子诊断与治疗杂志, 2021, 13(10): 1680-1684. doi: 10.3969/j.issn.1674-6929.2021.10.032

    DU X L, ZHANG D M, XU H. The relationship between PD-1, PD-L1, and Cyclin D1 protein expression and prognosis in ovarian cancer tissue[J]. Journal of Molecular Diagnosis and Treatment, 2021, 13(10): 1680-1684. doi: 10.3969/j.issn.1674-6929.2021.10.032
    [21]
    邓宇鹏, 许娜, 娄彤, 等. PD-L1在卵巢高级别浆液性癌预后中的价值[J]. 中国实验诊断学, 2020, 24(10): 1649-1653. doi: 10.3969/j.issn.1007-4287.2020.10.020

    DENG Y P, XU N, LOU T, et al. The value of PD-L1 in the prognosis of advanced serous ovarian cancer[J]. Chinese Journal of Experimental Diagnosis, 2020, 24(10): 1649-1653. doi: 10.3969/j.issn.1007-4287.2020.10.020
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(4)  / Tables(5)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (51) PDF downloads(9) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return